Summary The differential diagnosis of mesothelioma, primary adenocarcinomas and pleural metastases frequently causes problems. We have used the comparative genomic hybridization (CGH) technique on 34 malignant mesotheliomas and 30 primary lung carcinomas (adenocarcinoma, including bronchoalveolar carcinoma and large-cell anaplastic carcinoma) to compare their copy number changes and to evaluate the use of CGH to distinguish between these two types of tumour. In mesothelioma, gains of genetic material occurred as frequently as losses, whereas gains predominated over losses in carcinoma. In mesothelioma, the most frequent changes were losses in 4q, 6q and 14q and gains in 1 5q and 7p, whereas gains in 8q, 1 q, 7p, 5p and 6p were the most common changes in carcinoma. Amplification of KRAS2 was detected in two adenocarcinomas by Southern blot analysis. CGH showed gains in 12p in the same tumours. Statistically significant differences between the two types of tumour were detected in chromosomes X, 1, 2p, 4, 8q, 1 Oq, 1 2p, 1 4q, 1 5q and 1 8q. When comparing the frequency of gains and losses between mesothelioma and lung carcinoma using discriminant analysis, the sensitivity of CGH to differentiate mesotheliomas from lung carcinomas was 81% and the specificity 77%. The differences in DNA copy number changes between the two types of tumour suggest that they are genetically different tumour entities. Although CGH cannot be used as a definitive discriminatory method, we were able to distinguish between mesothelioma and lung carcinoma in a large proportion of the abnormal cases.
Malignant mesothelioma is a tumour derived from mesothelial cells lining the pleural and peritoneal spaces. About 80% of patients suffering from mesothelioma have a history of occupational asbestos exposure, which is considered a risk factor for its development (Wagner et al, 1960; Chahinian et al, 1982) . Genetic susceptibility, such as inherited glutathione S-transferase Ml and N-acetyltransferase-2 gene defects, has also been suggested as a contributing factor in asbestos-related mesothelioma (Hirvonen et al, 1996) .
The differentiation of malignant mesotheliomas from primary adenocarcinomas and pleural metastases can be difficult (Pisani et al, 1988; Brown et al, 1993; Weiss and Battifora, 1993) . The differential diagnosis is currently based on various morphological analyses, including a combination of histological and immunohistochemical stains as well as electron microscopy (Brown et al, 1993; Weiss and Battifora, 1993) . Generally, a panel of several diagnostic markers is used, the most common being carcinoembryonic antigen (CEA), epithelial antigen (Ber-EP4) and Leu-M1 (Brown et al, 1993; Skov et al, 1994) . These markers recognize molecules expressed by epithelial but not by mesothelial cells, and therefore the diagnosis of mesothelioma is based on negative immunohistochemical results. An antibody that reacts with mesothelioma but not with lung carcinoma has been described (Edwards and Oates, 1995) . However, this antibody does not stain formalin-fixed tissues. Recently, two antibodies (HBME-1 and calretinin) reacting with formalin-fixed mesothelioma cells have been reported (Miettinen and Kovatich, 1995; Doglioni et al, 1996) . Several cytogenetic studies have been performed on both mesothelioma and non-small-cell lung carcinoma (NSCLC), but no chromosomal aberration specific to either of the tumours has been found. Both show very complex karyotypes with multiple numerical and structural changes (Tiainen et al, 1989; Hagemeijer et al, 1990; Lukeis et al, 1990; Taguchi et al, 1993; Testa et al, 1994) .
Comparative genomic hybridization (CGH) is a powerful methdd for revealing DNA copy number changes, such as losses, gains and amplifications of DNA sequences, in the whole tumour genome in a single hybridization experiment. The method is based on in situ hybridization of differentially labelled tumour DNA and normal reference DNA together with unlabelled Cot-I DNA (blocks binding labelled repetitive sequences in both genomes) on normal metaphase preparations. DNA copy number changes are revealed by measuring the tumour-normal fluorescence intensity ratio for each locus in the target metaphase chromosomes (Kallioniemi et al, 1992) . The advantage of CGH compared with conventional cytogenetic analysis is that only DNA from the specimen is required; therefore, no culturing of the tumour is needed. Using this method, problems with low mitotic indices and difficulties in obtaining well-banded metaphases are avoided.
Furthermore, the genetic composition of marker chromosomes, homogeneously staining regions and double minutes (dmin) is resolved by CGH. However, the drawbacks are that neither balanced translocations, inversions, small deletions nor polyploidization can be detected.
In this study, we compare the copy number changes between mesothelioma and different types of adenocarcinoma and largecell anaplastic carcinoma (referred to as lung carcinoma in the text). We also evaluate the possibility of using CGH as a tool for distinguishing these two types of tumour. Squamous cell carcinoma of the lung does not usually present a problem for differential diagnosis and was not included. Further analysis using the Southern blot technique was performed using a probe for the KRAS2 gene to investigate the tumours that showed gains of genetic material in chromosome 12p using CGH. 
MATERIALS AND METHODS

Lung carcinoma
Ten adenocarcinomas, ten bronchoalveolar and ten large-cell anaplastic carcinomas were selected from the files of the Department of Pathology, University of Helsinki (Table 1) . The specimens were formalin fixed and paraffin embedded. We selected the ten most recently diagnosed carcinomas in each group with sufficient material for the analyses.
DNA extraction
Sections were examined and the tumour area was marked. All irrelevant material was cut away and a new paraffin block was made of the remaining tumour tissue that contained at least 60% malignant cells. Thirty 3-to 5 gm-thick sections were cut and DNA extraction was performed as described elsewhere (Miller et al, 1988; Isola et al, 1994) . DNA in peripheral blood specimens from healthy donors (male and female) was extracted according to standard procedures and used as reference in the CGH analyses.
CGH analysis
The CGH analyses were performed according to the method of Kallioniemi et al (1994) , with some minor modifications. In brief, 800 ng of fluorescein isothiocyanate (FlTC)-dUTP (Du Pont NEN Products, Boston, MA, USA)-labelled tumour DNA and 800 ng of Texas Red-dUTP (Du Pont)-labelled normal reference DNA together with 20 jig of unlabelled human Cot-I DNA (Gibco BRL, Gaithersburg, MD, USA) in 10 jl of hybridization buffer [50% formamide, 10% dextran sulphate, 2xSSC (lxSSC is 0.15 M sodium chloride/0.015 M sodium citrate, pH 7)] were denatured at 75°C for 5 min and applied to normal lymphocyte metaphase preparations. Before hybridization, the preparations were stored in a fixative solution (methanol-acetic acid, 3:1) for one night, pretreated in 2xSSC at 40°C for 30 min and dehydrated in a series of 70%, 85% and 100% ethanol. The preparations were denatured at 65-670C for 2 min in a formamide solution (70% formamide/2xSSC) followed by dehydration on ice as described above and treatment with proteinase K. Hybridization (2-3 days at 37°C) was followed by washes to remove unspecifically bound DNA, after which the preparations were counterstained with 4, 6-diamidino-2-phenyl-indole-dihydrochloride (DAPI; Sigma, St Louis, MO, USA) and covered with an antifade solution (Vector Laboratories, Burlingame, CA, USA). To confirm the CGH results, additional hybridization experiments using the reverse-labelling system, i.e. tumour DNA labelled with Texas Red and reference DNA with FITC, were performed on some specimens.
Digital image analysis, interpretation and quality control of the CGH results An Olympus fluorescence microscope and the isis digital image analysis system (MetaSystems, Altlussheim, Germany) based on a high-sensitivity integrated monochrome CCD camera and an automated CGH analysis software package were used to analyse the hybridization (for details, see Kivipensas et al, 1996) . A region in a chromosome was considered as being over-represented (gained) when the ratio exceeded 1.17 and under-represented (lost) when the ratio was less than 0.85. These cut-off values were based on negative control hybridization experiments, i.e. hybridization of two normal DNAs. Only ratio changes that exceeded the fluctuation seen in the negative control experiments were interpreted as evidence of a real gain or loss of DNA sequences. Furthermore, positive control experiments with tumour DNA of known DNA copy number changes (both losses and gains) were performed to confirm the cut-off values mentioned above. In order to distinguish --between different levels of gain/ratios exceeding the values of 1.3 or 1.5 were considered as amplifications or high-level amplifications respectively. Furthermore, intra-experiment standard deviations for every position in the CGH ratio profiles were calculated from the variation of the ratio values of all homologous chromosomes within the experiment. Confidence intervals for the ratio profiles were then calculated by combining them with an empirical inter-experiment standard deviation and estimating error probability of 1% based on the t-distribution. The heterochromatic regions in chromosomes 1, 9 and 16, the p-arms of the acrocentric chromosomes and the Y chromosome were excluded from the analyses because of suppression of hybridization with Cot-I DNA in these regions. Gains (.1.17 and <1.3) of genetic material in chromosomes lp32-pter, 16p, 19 and 22 were not included because of the false-positive results revealed in these chromosomal areas in the negative control experiments.
Southern blot analysis The Southern blot method was used to investigate possible amplification of the KRAS2 gene (probe p640, provided by R Weinberg) in (Peltomaki et al, 1991; Monni et al, 1996) .
Multivariate analysis
The calculated frequencies of DNA copy number changes and the statistical analyses were based on those tumours that had either gains or losses of genetic material.
British Journal of Cancer (1998) 77(2), 260-269 Discriminant analysis was used to distinguish between diagnostic groups based on observed DNA copy number changes. We began by using a linear discriminant function (Fisher, 1936) selection criterion for allocating a tumour to the a priori specified diagnostic group to which it has the maximum a posteriori probability of belonging. This Bayes rule can be linked to the Mahalanobis distance (Mahalanobis, 1936) by assuming that the groups are jointly distributed multivariate normal within the same covariance matrix. To calculate the above discriminant analysis functions, we used the discr, ida and qda programs implemented in the S-PLUS system (Venables and Ripley, 1994 Univariate analysis Table 3 gives the mean value and standard deviation of the number of gains and losses of DNA sequences detected in the two different main types of tumour and in the separate histological subgroups. Although differences in the frequency of gains and losses were detected between mesothelioma and lung carcinoma, they were not statistically significant (Fisher's exact test). However, when focusing on separate chromosomes, significant differences were seen in X, 1, 2p, 4, 8q, 10q, 12p, 14q, 15q and 18q (Table 4) . There was no statistically significant difference between the DNA copy number changes detected in separate chromosomes in the three histological subgroups of mesothelioma. When combining tumours from the fibromatous and mixed group, which is pennissible because of clinical and prognostic similarities, a gain of genetic material in 15q was found to be more common in epithelial tumours (n = 14) than in the fibromatous mixed group (n = 13) [risk ratio (RR) 6.5, 95% confidence interval (CI) 1.3-39.3]. Statistically significant differences in losses and gains of genetic material were not detected between the three types of lung carcinoma. When considering adenocarcinoma and bronchoalveolar tumours as one group (n = 16), a gain in lq occurred more often in them than in the tumours in the large-cell anaplastic carcinoma group (n = 10) (RR 2.7, 95% CI 1.2-7.8).
Mesothelioma Twenty-seven out of the 34 mesotheliomas showed DNA copy number changes. Gains of genetic material occurred as frequently as losses (Table 3) . High-level amplifications were only detected in 1 lq and 12p (Table 1 and Figure 1 ). The most common aberration in the mesotheliomas was a loss of DNA sequences in the long arm of chromosomes 4 and 6 in 10 of the 27 (37%) informative tumours. The minimal common region of loss extended in chromosome 4 from the 4q centromere to band q24 and 4q33 to the q-telomere and in chromosome 6 it was only band q22. Losses occurred frequently in the long arms of chromosomes 13 (q21-q22) and 14 (q21) and in the short arm of chromosome 9 (p21) in 22%, 33% and 22% of the abnormal specimens respectively (Table 1, Figures 1 and 2) .
The most recurrent gain of DNA sequences was detected in the long arm of chromosome 15 (q23-qter) in 9 of the 27 (33%) informative cases. There were three amplifications among these gains. Other regions commonly gained in the abnormal tumours were the short arms of chromosomes 5 (pcen-pter, 22%), 7 (pcen-pter, 26%) and 8 (pcen-p12, 22%) and the long arm of chromosome 7 (qcen-qter, 22%). Among these gains one amplification was detected per chromosome (Table 1, Figures 1 and 2 ).
Lung carcinoma DNA copy number changes were detected in 26 of the 30 specimens evaluated. Gains of genetic material predominated over losses with a ratio of 4.6:1 (Table 3 ). There were high-level amplifications in 5p, 7p, 8p, 8q, 12p, 12q and 21q (Table 1, Figures 1 and 2) .
A gain in DNA sequences in the long arm of chromosome 8 (q23-qter) was the most recurrent aberration found in 17 of the 26 (65%) informative tumours. Seven of these were amplifications and three were high-level amplifications. More than half (62%) of the informative specimens had gains in the long arm of chromosome 1 (q22-q31). Four amplifications and 12 gains were observed in this area. Gains were also frequent in the short arms of chromosomes 6 (pcen-p21.3, 31%), 5 (pl4, 35%) and 7 (pcen-p21, 42%). The last two included one high-level amplification and three amplifications (Table 1, Figures 1 and 2) .
Losses of DNA sequences were most common in the long arm of chromosome 6 (qcen-q23). These aberrations were found in 4 of the 26 (15%) abnormal tumours. Other chromosomal areas that were lost in three or four tumours were the short arms of chromosomes 8 (pcen-pter, 15%) and 17 (pcen-pter, 12%), the long arm of chromosome 18 (qcen-qter; 12%) and the whole X chromosome (pter-qter; 12%) ( Table 1, Figures 1 and 2 ).
Southern blot analysis
Amplification of KRAS2 was detected in two of the seven tumours with a gain of genetic material in 12p. Both of these were regular adenocarcinomas (case nos 40 and 43). Compared with the negative controls, these carcinomas showed increased dosages (3.7-and 8.2-fold) of KRAS2 (Figure 3 ). In the other five tumours, the analysis failed because of the poor quality of the DNA.
DISCUSSION
The main result in our study is that there is a difference between the pattem of DNA copy number changes in mesothelioma and that in lung carcinoma. By combining the occurrence of gains and losses of genetic material in the individual tumours, we were able to predict the correct type of tumour in 41 of the 53 informative cases. When comparing DNA copy number changes in single chromosomes, significant differences were detected in ten chromosomes.
Discriminant analysis for normal populations assumes that the joint distribution of all predictors is multivariate normal. In practice, this assumption is not always valid, and even the predictor variates are only approximately normal. Therefore we have to rely on the robustness of the applied procedure to depart from normality. The detected chromosome changes were originally coded as 63 indicator variates. The sum of binary (0, 1) variates tends to be normally distributed, and the transformation of the summed variates helps to approximate this distributional assumption. (We note parenthetically that the reduction of the number of variates must be performed without regard to their relationship to the outcome variate, i.e. the type of tumour -otherwise the selection procedure will be biased.) To check the stability of the results, we conducted a logistic discriminant analysis that makes fewer assumptions about the distributions of the variates. This method yielded results similar to those obtained by the ida and qda methods.
Nevertheless, the size of the subgroups of classified tumours was too small -in particular, there were only five fibromatous mesotheliomas -to form reliable predictor models. In practice, in order to have predictive discrimination that validates a new series of tumours, the number of variates selected for the discriminant function should be no more than the number of tumours in the sample that was used in fitting the model divided by ten (Harrel et al, 1996) . The size rule applies because we used four (or two) summary variates on a sample of 53 (i.e. 4 < 53/10 5). To discriminate between the two diagnoses (mesothelioma and lung carcinoma), the number of tumours in the less frequent group (26) should be at least roughly ten times higher than the number of predictors (10 x 4 = 40 or lO x 2 = 20); here the rule does not apply when four predictors are used.
Our primary measure of accuracy of classification was the error (or misclassification) rate, as this is the quantity that the Bayes rule minimizes. The most stringent test of a predictor model is an extemal validation -the application of the estimated model to a new patient population. Unfortunately, we did not have another series of tumours to test the performance of the model. However, the error rate on a randomly chosen set from the whole population will be an unbiased estimator. For this cross-validation (Efron, 1983) , we first randomly allocated 53 tumours into ten mutually exclusive subsamples. We then left out a subsample, estimated the discriminant function model on the remaining sample and used the fitted model to classify the previously drawn subsample. We replicated this procedure for the other nine subsamples. The cross-validated error rate was then formed by averaging one minus the posterior probability assigned to the selected class. Another advantage of this technique is that it does not depend on the correctness of the supplied classification based on the histological diagnosis (Venables and Ripley, 1994) . The cross-validated result for the previously obtained error rate of 21% was 26%, indicating a fair reliability of the model to discriminate between mesothelioma and lung carcinoma.
The DNA copy number changes detected in mesothelioma in this analysis, such as losses of genetic material in lp, 4q, 6q, 9p, 13q, 14q and gains in 5p and 7p, are supported by previous cytogenetic and CGH studies, although with some differences in frequency of occurrence (Tiainen et al, 1989; Hagemeijer et al, 1990; Taguchi et al, 1993; Kivipensas et al, 1996; Bjorkqvist et al, 1997) . These chromosomal regions probably carry important genes for the development and progression of mesothelioma. Losses of DNA sequences in 13q were detected in six tumours in this study. Five of these showed a loss in 13ql4 in which the RBI tumoursuppressor gene is located. However, a study by Van der Meeren et al (1993) on mesothelioma cell lines suggests that inactivation of RBI is not a critical step in the development of mesothelioma.
The most common copy number changes in non-small-cell lung carcinoma (NSCLC) in this study were gains in 8q, lq, 7p, 5p and 6p (in decreasing order of frequency). Cytogenetic analyses of NSCLC have detected, on average, more losses than gains of chromosomal material (Lukeis et al, 1990; Testa et al, 1994) . These results are to some extent in contrast to ours, because we detected over four times more gains than losses. However, gains in lq, 7 and 12q have been frequent findings by cytogenetic analysis (Lukeis et al, 1990; Testa et al, 1994) and they were also frequent in our study. Because marker chromosomes are common cytogenetic findings, it is obvious that some of the chromosomal material thought to be lost resides in them. CGH is a DNA-based method and therefore the genetic material in marker chromosomes as well as in dmin is also analysed. Furthermore, CGH reveals only clonal aberrations that exist in at least 50% of the cells, meaning that clonal aberrations found only in a small proportion of the cells will not be detected (Kallioniemi et al, 1994) . Some of the DNA copy number changes seen in our study, particularly high-level amplifications, represent new findings that may have an important role in the tumorigenesis of NSCLC. Gains of genetic material in the long arm of chromosome 8 are not often found in cytogenetic analyses. However, the presence of isochromosome 8q has been associated with primary adenocarcinomas (Jin et al, 1988) and gains in 8q have been reported to be frequent in pleural effusions from NSCLC patients (Lukeis et al, 1993) . In our CGH analysis, this particular aberration (including three high-level amplifications) occurred in 65% of the informative tumours. Amplification of the MYC oncogene has been detected in some NSCLCs (Cline and Battifora, 1987; Slebos et al, 1989) . MYC resides in the minimal common region of overlap (8q23-qter) in our study and therefore it is likely to be one of the amplified genes.
The difference in the occurrence of losses and gains of genetic material detected in our study may suggest that mesotheliomas and lung carcinomas develop and progress in different ways. This hypothesis is supported by molecular analyses that have demonstrated that mutations in the tumour-suppressor gene P53 in 17p and the oncogene KRAS2 in 12p are frequent in NSCLCs but not in mesotheliomas (Metcalf et al, 1992; Ridanpiia et al, 1994) . We detected amplification of KRAS2 in two adenocarcinomas and a gain of genetic material in 12p in seven carcinomas, supporting the role of gene amplification as an alternative pathway by which KRAS2 is activated.
Similarities, such as gains of genetic material in 5p, 6p and 7p, between mesothelioma and lung carcinoma were also found. We detected a gain in 7p in seven mesotheliomas and 11 lung carcinomas (including one high-level amplification). The EGFR gene, located in 7pl2-pl3, may be one of the altered genes and may therefore be important in the tumorigenesis of both types of tumour. The putative tumour-suppressor genes MTS2 and MTSJ in 9p2l are deleted or mutated in both types of tumour (Xiao et al, 1995a and b) . We detected deletions in 9p in six mesotheliomas but only in two carcinomas. Based on previous published cytogenetic data on mesothelioma and NSCLC, a higher frequency of losses in 9p was to be expected (Hagemeijer et al, 1990; Lukeis et al, 1990; Taguchi et al, 1993; Testa et al, 1994) . It is likely that deletions in 9p existed in our specimens but were not detected because of intratumour genetic heterogeneity.
In conclusion, we found differences in DNA copy number changes between mesothelioma and lung carcinoma, suggesting that they are genetically different tumour entities. Although CGH cannot be used as a definitive discriminatory method, based on the CGH results, we were able to distinguish between mesothelioma and lung carcinoma in 77% of the abnormal cases. In addition, our CGH results of primary adenocarcinoma and large-cell anaplastic carcinoma of the lung revealed new findings of losses, gains and amplifications of genetic material, which could be important for their development and progression.
